Visudyne is a brand name of verteporfin, approved by the FDA in the following formulation(s):
VISUDYNE (verteporfin - injectable; injection)
Manufacturer: QLT
Approval date: April 12, 2000
Strength(s): 15MG/VIAL [RLD]
Has a generic version of Visudyne been approved?
No. There is currently no therapeutically equivalent version of Visudyne available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Visudyne. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Wavelength-specific cytotoxic agents
Patent 5,095,030
Issued: March 10, 1992
Inventor(s): Levy; Julia G. & Dolphin; David & Chow; Jack K. & Sternberg; Ethan
Assignee(s): University of British Columbia
A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.Patent expiration dates:
- September 9, 2011✓
- September 9, 2011
Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
Patent 5,707,608
Issued: January 13, 1998
Inventor(s): Liu; Ron
Assignee(s): QLT PhotoTherapeutics, Inc.
Liposomal compositions containing green porphyrins as photosensitizers are improved by enhancing the ratio of phospholipid to photosensitizer and by conducting the hydration an sizing of the liposomes in the composition at low temperature.Patent expiration dates:
- August 2, 2015
- August 2, 2015
Vision through photodynamic therapy of the eye
Patent 5,756,541
Issued: May 26, 1998
Inventor(s): Strong; H. Andrew & Levy; Julia & Huber; Gustav & Fsadni; Mario
Assignee(s): QLT Phototherapeutics Inc
Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects,Patent expiration dates:
- March 11, 2016✓
- March 11, 2016
Method of activating photosensitive agents
Patent 5,770,619
Issued: June 23, 1998
Inventor(s): Richter; Anna M. & Waterfield; Elizabeth & Levy; Julia G.
Assignee(s): University of British Columbia
A method of administering photodynamic therapy begins with administering to an animal an effective amount of a photosensitizing agent which is less than about one half of the usual clinical dose for the photosensitizing agent. Then, following a post injection interval which is less about one quarter of the usual post injection interval, an effective dose of light which is less than about one half of the usual clinical dose of light used in conjunction with the photosensitizing agent is administered to the animal.Patent expiration dates:
- January 6, 2015✓
- January 6, 2015
Use of green porphyrins to treat neovasculature in the eye
Patent 5,798,349
Issued: August 25, 1998
Inventor(s): Levy; Julia & Miller; Joan W. & Gradoudas; Evangelos S. & Hasan; Tayyaba & Schmidt-Erfurth; Ursula
Assignee(s): The General Hospital Corporation
Quadra Logic Technologies, Inc.
Massachuesetts Eye & Ear Infirmary
Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.Patent expiration dates:
- August 25, 2015✓
- August 25, 2015
Liposome compositions of porphyrin photosensitizers
Patent 6,074,666
Issued: June 13, 2000
Inventor(s): Desai; Narendra Raghunathji & Agha; Bushra J. & Kale; Kalidas Madhavrao
Assignee(s): QLT Phototherapeutics, Inc.
Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrins (BPD) having light absorption maxima in the range of 670-780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.Patent expiration dates:
- February 5, 2012
- February 5, 2012
See also...
- Visudyne Consumer Information (Wolters Kluwer)
- Visudyne Consumer Information (Cerner Multum)
- Visudyne Advanced Consumer Information (Micromedex)
- Visudyne AHFS DI Monographs (ASHP)
- Verteporfin Consumer Information (Wolters Kluwer)
- Verteporfin Consumer Information (Cerner Multum)
- Verteporfin Intravenous, Injection Advanced Consumer Information (Micromedex)
- Verteporfin AHFS DI Monographs (ASHP)
No comments:
Post a Comment